Pulsed Electric Field (PEF) treatment of progressive non-small cell lung cancer concurrently treated with immune checkpoint blockade: A case report

Marcelo Jimenez; Jose M Fernandez; William S Krimsky

doi:10.1016/j.rmcr.2024.102018

Pulsed Electric Field (PEF) treatment of progressive non-small cell lung cancer concurrently treated with immune checkpoint blockade: A case report

Respir Med Case Rep. 2024 Mar 29:49:102018. doi: 10.1016/j.rmcr.2024.102018. eCollection 2024.

Authors

Marcelo Jimenez^{1

2

3}, Jose M Fernandez¹, William S Krimsky⁴

Affiliations

¹ Salamanca University Hospital, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.
² University of Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.
³ Instituto de Investigación Biomédica de Salamanca (IBSAL) Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.
⁴ Galvanize Therapeutics, Inc. 3200 Bridge Parkway Drive, Redwood City, CA, 94065, USA.

Abstract

Pulsed Electric Field (PEF) energy was delivered at the time of confirmational biopsy to ablate recurrent NSCLC in the right upper lobe (RUL) of the lung after recurrence while on durvalumab consolidation. The patient tolerated the procedure and exhibited stable disease at 6 and 12 months from time of durvalumab discontinuation and PEF treatment, respectively. This report represents the first use of the Aliya™ PEF system as a minimally invasive modality with potential to re-sensitize disease to immune checkpoint blockade (ICB) upon progression.

Clinicaltrialsgov identifier: NCT04773275.

Keywords: Case report; Immune checkpoint blockade; NSCLC; Pulsed electric field (PEF).

Publication types

Case Reports

Associated data

ClinicalTrials.gov/NCT04773275